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Abstract: To explore long-term changes in intra and inter-class choices between generic compounds,
this paper investigates the market trends of two antihypertensive drug classes that have closely related
pharmacological mechanisms—angiotensin convertase enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs). We analysed the development of ACEI and ARB markets between 2001 and
2016 in nine European countries, covering the genericization transition periods of both therapeutic
groups. The analysis was undertaken on the level of the active pharmaceutical ingredients (API)
and focused on international and country-specific diffusion patterns. Comparison of ARB and ACEI
therapies shows that although ARBs became off-patent during the observed period, and have a
clinical advantage in terms of the adverse event profile over ACEIs, the increasing dominance of
ARBs cannot be identified. One explanation is that ACEI therapies became generics earlier, relocating
competition to the level of brands, while competition among ARBs remained at the level of the APIs.
As for intra-class drug preferences, it was observed that the long-term trends show that ramipril
outperformed its ACEI competitors, even though the kinetics and the rank order of preferred active
compounds were inconsistent among markets. The diffusion of clinically preferable therapies seems
to be ultimately supported by generic entries. In Eastern European countries, the emergence of generic
markets has not only improved access to ACE inhibitors and ARBs, but has been a prerequisite for
changing preferences. In contrast, genericization resulted in the relative anchoring of prior, branded
era-based preferences in some Western European countries, which may be attributed to the role of the
cessation of promotion and the fixity of prescription behaviour.
Keywords: pharmaceutical therapies; market performance; genericization; diffusion; Europe
1. Introduction
1.1. Introduction
Ideally, when choosing a therapy, physicians select the option that ensures the best
outcome for patients. By the time a whole class of drugs becomes off-patent, significant
scientific knowledge and medical experience has been gathered about each individual
active pharmaceutical ingredient in the group, which theoretically permits an informed,
evidence-based prescription choice, even if treatment guidelines formulate class-level recom-
mendations. While the impact of patent losses on pharmaceutical spending and switching
from branded products has been of intense scientific interest, less is known about how the
generic markets of specific drug classes develop in the long term. In relation to the two
drug groups under analysis, the first-in-class ACE inhibitor captopril was approved in 1981,
followed by a dozen other active moieties, while in terms of ARBs, losartan was approved in
1995, followed by several active ingredients. This abundance of active ingredients provides
an appropriate basis for our research.
Int. J. Environ. Res. Public Health 2021, 18, 9429. https://doi.org/10.3390/ijerph18189429 https://www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2021, 18, 9429 2 of 19
In our analysis, we accept the principles of the evidence-based medicine (EBM) ap-
proach and investigate whether diffusion is more likely to happen with therapies with more
favourable clinical profiles [1,2]. While the EBM model represents an appealing framework
that combines global scientific knowledge with individual insights and needs, some practi-
cal limitations should be kept in mind. New medical advances and study findings become
available every day; however, the continuous incorporation of fresh medical information is
hindered by various phenomena in clinical practice [3,4].
In the article from 2017, Kovács and Simon analysed the effect of clinical evidence and
price on prescription drug sales, hypothesizing that generic markets favour those drug
classes or active moieties from direct competitors that represent the highest therapeutic
value. Their assumption, based on EBM principles, was that an absolute clinical ranking
(Appendix A, Figure A1) can be defined based on the clinical differences among the active
ingredients used in the same indication [5]. The findings of the article assume a positive
correlation between clinical evidence and market performance. However, the authors drew
their conclusions based on data about ACEI and ARB sales in a single year.
Realistically, the sales or the market position of a medicine, drug class, or pharmaceu-
tical substance cannot be expected to remain unchanged over time. In the present study, we
explore and describe the dynamics of the selected generic markets, investigating whether
preferences for ACE inhibitors and ARBs have changed over time on a macro level. Besides
enquiring about the changes in the overall use of active moieties and drug classes, the
authors intend to obtain insights about prescribing characteristics, with special attention
paid to the following questions:
# In terms of long-term trends, how does clinical evidence affect market performance?
# Have preferences for groups of drugs and for active ingredients been affected by the
genericization of ARBs and ACE inhibitors in European markets?
# Can international or country-specific interrelationships be identified based on long-
term prescribing trends?
1.2. The Life Cycle of Drugs and the Market Characteristics of Generic Drugs
The pharmaceutical market is driven by constant innovation, yet the pharmaceutical
market cannot be simplified to the interaction between the supply of innovative drug
manufacturers and the demands of patients. As for the manufacturing side, in addition
to innovative companies, competition among generic players is becoming increasingly
intense. While generic drugs are gaining ground, drug policies that aim to cut costs are
becoming widespread. Although a significant proportion of drugs that are designed to
treat common diseases such as hypertension and diabetes have lost their patent protection,
the range of available therapies has also changed in recent years.
Drug development and drug pricing are also defined by law and regulations [6,7].
There are many regulatory techniques for affecting both demand and supply, in relation
to which national drug policy makers expect that costs are controlled, funding sustained,
prices decreased, and access to medicines improved [8].
In addition to those drugs that are new from every perspective (i.e., first-in-class) [9],
other original drugs with different active ingredients but a similar mode of action can also
be introduced to the market.
In principle, me-too and follow-on drugs increase the therapeutic potential of the
market, contributing to well-being and price reductions; furthermore, their approval
encourages further market development. However, some believe that they fail to represent
genuine innovation, and that price competition may not be effective, as in certain cases,
they may lead to greater expenditure [10–12].
As long as patents provide protection (typically 20 to 25 years), or data exclusivity
or market exclusivity is maintained, generic competitors cannot be introduced to market.
As innovation costs are huge, the time it takes for an innovator to launch a generic drug
to the market is enormously important, and during this period, their investment can be
recouped [13,14].
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With the end of the monopoly on an original product, generic drugs basically act to
lessen spending on pharmaceuticals. Price reductions can lead to better access to drugs and
an increase in sales of an active ingredient [15,16]. However, it should not be generalized
that generic drugs inevitably mean price reductions, or that with the start of generic com-
petition, the perfect principles of free competition prevail. With the entry of generic drugs,
the price of an original branded product typically remains the same or even increases (the
“paradox of generics”). This may be attributed to prescribers susceptible to pharmaceutical
promotion continuing to prescribe the original brand [17].
The speed of any decrease in price after the loss of exclusivity depends on the price
prior to the expiry of patents and the size of the market, both of which factors define
how attractive generic companies find it to enter the market with a cheaper version of a
product [18]. In very small markets, it may not be attractive for a generic manufacturer to
launch a generic product, thus the innovator can remain the sole distributor of a drug for a
long time [19]. Thus, the average duration until the entry of the first generic drug varies
from country to country, just as the proportion of prescriptions of generics does (“generic
penetration”) [20]. Furthermore, with the acquisition of competitors, generic companies
may reduce competition. In extreme situations, this may result in a monopoly situation
and drastic price increases [21].
To protect their markets, innovative manufacturers attempt to defer the market entry
of generic drugs in different ways. In addition to obtaining additional market protection
(e.g., new registrations, or the registration of paediatric indications), the past few decades
have seen various attempts at improving competitive positions. An example of this is the
introduction of a new, patent-protected drug by family extension, and switching patients
before genericization. In this way, a part of an innovator’s market can thus be protected
(“product hopping/evergreening”) [22,23].
Furthermore, several such methods have been used that raise concerns related to
different areas of competition law. A good example is patent manipulation—when an
innovator attempts to make market entry difficult by using patents that fail to involve
significant innovation, or the innovator tries to reach a patent settlement with manufac-
turers, aiming to enter the market to prevent the latter from attacking their patents and
bringing their own products to market [22,23]. In the European market for ACE inhibitors,
such practices—generic competition undermined by patents—have been identified. Servier,
the developer of perindopril, has filed numerous patent applications that lack genuine
innovation aimed at preventing the market entry of generic drugs, also seeking to obtain
circumventing technologies. The company attempted to reach patent agreements with
pharmaceutical companies considering entry to the generic market between 2005 and
2007. Finally, the European Commission ordered Servier and the companies with which
Servier had reached patent settlements to pay a fine of over EUR 400 million for violating
competition law [24].
As cheaper bio-equivalent drugs may reduce costs and improve access to therapies,
health policy strongly prioritizes the promotion of generic drugs. Therefore, measures
for promoting the use of generic drugs can often be identified in relation to regulations
applied to pharmaceutical markets. These include, among other areas, encouraging generic
development (e.g., public authorities issuing development guidelines), substitution by
generics in the distribution and prescription process, ordering drugs according to their
international non-proprietary name (INN), or incorporating financial incentives into the
financing of physicians’ and pharmacists’ practices. Methods used to subsidize medicines
and drug pricing vary from country to country, but a very frequently used and somewhat
controversial method is so-called reference pricing. This involves the price of a subsidized
preparation being tied to its cost in another country (“external reference pricing”) or to
the price of similar drugs (“internal reference pricing”) [8,25]. However, following the
economic crisis of the 2000s, an increasing number of countries considered it important
to cut back on drug spending, and thus health policy measures aimed at promoting the
prescription of generic drugs are increasingly being used [26].
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1.3. Factors Influencing the Choice of Drug Therapies and Drug Sales
Prescription drug sales are basically defined by the following factors: the number of
prescriptions filled out by physicians; whether the prescriptions are actually dispensed;
and what kind of products patients receive for their prescription in pharmacies. On the
basis of the latter, Danzon and Furukawa proposed distinguishing between two types of
generic market: physician-defined markets, where physicians can decide which product
from which generic manufacturer to prescribe; and pharmacy-driven markets, where the
pharmacy basically decides which active ingredient from which manufacturer to sell [27].
In our analysis, the UK can be located in the latter category, while in Italy, Germany, Spain
and France, physicians’ prescribing decisions have been found to be the main factor. Partly
due to the drug policy measures that were the result of the economic crisis of the late 2000s,
the distinction between the two approaches started to blur in several countries. At the
very least, the latter changes strengthened the role of pharmacies [28]. In 10 EU countries,
mandatory active-ingredient-based prescription or mandatory generic substitution had
been introduced into the legal system by 2016. In other EU countries, this was encouraged
in different ways [29].
There are many publications about the mechanisms involved in and motivations for
medical prescription-related decisions and the market introduction of new therapies. In
these publications, various factors that may potentially influence the diffusion of new
therapeutic options are identified at the micro- and meso-levels. These include physician-
related factors (socio-demographic status, scientific profile, prescription habits, exposure to
various forms of promotional activities and contagion through social networks), character-
istics of the medical practice, types of patients treated, and medication. The drug-related
factors affecting such decisions may be directly measurable ones (such as the marketing
expenses of the manufacturer, general acceptance of the drug, therapeutic novelty, number
of competitors, or price of the drug) in addition to actual medical characteristics (address-
ing unmet needs, advantage over available alternatives, or safety-and-efficacy-related
perceptions) [30–32].
Rogers’ diffusion model shows that innovation diffuses across societies through vari-
ous communication channels over time [33]. Plotting the proportion of new technology
users over time, the model describes (by default) a sigmoid curve, as it distinguishes five
groups—innovators, early adopters, early majority, late majority and laggards—based on
their attitude towards a new process (in our case, towards a new active ingredient) [34]. At
the individual level, five stages of the adoption process are distinguished—from learning
about the new opportunity to committing to its use: knowledge/awareness, persuasion,
the decision to reject or adopt, implementation, and confirmation. Following this approach,
Rogers’ model combines macro-level processes with micro-level events, which, when ap-
plied to the pharmaceutical market, can lead from individual medical therapeutic decisions
to the market penetration of innovative drugs.
With regard to specific therapeutic options and the choice of active ingredients, Denig
attributed a decisive role to the amount of medication recommended by physicians (the
evoked set). According to her model, physicians either attempt to select prescribed med-
ication out of habit, or actively seek the solution to a clinical question. The impact of the
decision will influence the decision-making process and will be incorporated into experience
and knowledge—the basis of future therapeutic choice—and drug selection habits. Accord-
ing to the studies Denig conducted among Dutch hospital doctors in the 1990s, the size of
the evoked set was between 1.7 (platelet aggregation inhibitors) and 5 (antihypertensive
drugs) on average, depending on the group of drugs [35].
An article about research into the marketing strategy of ACE inhibitors stated as early
as in the early 1990s that Servier’s perindopril (Coversyl) also affected national preferences
among French prescribers [36]. The manufacturers of the 14 ACE inhibitors present on the
branded market attempted to distinguish themselves from other members of the group
with various messages: with regard to older drugs (captopril, enalapril), by primarily
emphasizing new indications (heart failure and heart attack post condition, and diabetes-
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related hypertension); by referring to new entrants (e.g., ramipril, perindopril, quinapril),
by stressing their success at preventing organ damage; while very recent ones (trandolapril,
benazepril) have attempted to build their communication more on aspects of convenience.
Although drugs that act on the same biological target show strong similarity in principle,
due to their different chemical structures, they may behave differently in the human body,
whether pharmaco-kinetically or pharmacodynamically. Besides this, it may not be possible
to obtain the same clinical evidence for each active ingredient. This is the case with ACE
inhibitors, too. Although all these drugs were registered for the treatment of hypertension,
not all drugs are associated with clinically based supporting data about their effects on other
conditions, such as improving the survival chances of heart failure or heart attack [37–39].
From a practical point of view, there may be supporting arguments for formulating group-
level recommendations, because guideline messages can be simplified and clarified, and the
amount of data that practitioners need to remember can be reduced. Nonetheless, in their
investigation into prescription data of OECD countries, Maggioni et al. revealed that nearly
a quarter of heart failure patients either did not receive ACEI or ARB treatment, or not in the
right dose, in opposition to the suggestions of the treatment guidelines [40].
Concerns have been raised about the quality of information provided by the phar-
maceutical industry in their marketing [41–43], and there is evidence that physicians tend
to be critical about the pharmaceutical industry either in the scientific literature [44] or
even among their colleagues [45]. Nonetheless, promotional activity is certainly a factor
that should be considered in drug prescription decisions and in the processes of the phar-
maceutical market, even if the effects of such promotion are somewhat contradictory. A
number of studies indicate that marketing tends to have a detrimental effect on the quality
of prescriptions but increases the demand for medicines, while other studies found no
significant correlation between these factors. The only conclusion that Spurling et al. were
able to come to after reviewing the relevant literature was that there is no evidence that
prescription habits can be improved by promotion [46]. It is interesting from the perspec-
tive of this study that Greving et al. found in their research among Dutch physicians about
antihypertensive drugs in the early 2000s that physicians who tend to rely more heavily on
pharmaceutical industry information were more likely to start to prescribe ARBs to their
patients [47].
According to Venkataraman and Stremersch, marketing effectiveness is modified by
the efficacy and side effects of a drug [48]. The picture is further complicated by the fact that
it does matter what kind of information is made available to physicians in the various life
stages of the product, because emphasizing a certain product characteristic in a competitive
environment can be beneficial or detrimental to product sales [49].
An interesting feature of drugs is that they are experience goods. Namely, whether
individual drugs are good for patients transpires only after they have been taken. Crawford
and Shum, in their study on anti-ulcer drug prescriptions, concluded that patients were
fundamentally risk-averse and that initial uncertainty about drugs quickly disappeared,
so they were not interested in switching drugs and continued treatment with the first
drug of their choice. These authors also called attention to the fact that marketing that
creates highly positive consumer perceptions may lead to market concentration, even if the
alternatives that are available are essentially similar [50].
2. Materials and Methods
2.1. Data Used in the Investigations
Information concerning market performance was obtained from the IQVIA Health
MIDAS database made available by Gedeon Richter Plc. IQVIA MIDAS data combine
country-level data, healthcare expertise and therapeutic knowledge in 90+ countries to
deliver data in globally standardized forms to facilitate multi-country analyses, acting as a
leading source of insight into international market dynamics relating to the distribution
and use of medicines. IQVIA MIDAS data are designed to support multi-country analyses
of trends, patterns and similar types of analyses. All of the calculations, algorithms and
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methodologies used to produce these estimates of real-world activity makes the data highly
reliable for these intended uses.
Quarterly aggregate data were obtained for the period from 2001 to 2016 on ACE
inhibitor and ARB sales broken down into two-to-five-year periods for nine countries
(France, Germany, Hungary, Italy, Poland, Romania, and the Netherlands; sales figures
for the latter were available from 2004 onwards only). The selection of countries for the
descriptive analysis was based on the cross-sectional study by Kovács and Simon [5]. The
database contained drug class, active ingredient, and brand data, providing data about the
sales of marketed branded and generic products from different manufacturers containing
the same active ingredient. We retrieved data from the database for the main group of C09
ATC entirely according to the brand and mechanism of action, thus including within the
two groups of mechanisms both drug products with a single active component and drug
combination products (codes C09A and C09B, as well as codes C09C and C09D at ATC
level 4). On the first level of query, distribution by form of dosage was examined. Since
99.9% of ACE inhibitors are taken orally worldwide, only oral pharmaceutical forms were
filtered during later queries. Therapeutic group–country-, active pharmaceutical ingredient–
country-, and active pharmaceutical ingredient–country–brand-level queries were also
undertaken for the investigated markets. To indicate pharmaceutical sales, manufacturer
revenues (thousand euros, MNF) and sales volumes (thousand ‘counting units’, CU; that is,
pills, capsules, sachets, etc.) were taken into account in subsequent calculations. In order
to ensure comparability, we analysed sales volume data in the relevant countries: more
precisely, we compared the sales ratio that describes each API’s market performance in
each country under investigation. We also took into account the fact that the APIs differ
concerning defined daily dose (DDD), and that different strengths are available. Days of
treatment (DOT) can be known only if we have all of the mentioned information about
the APIs. We retrieved information about sales volume (thousand tablets) from the IMS
database in the following format: API-strength-country. From these data, we were able
to calculate whether the ratio of sales volume (later defined as CU/MAT) was linearly
proportional to DOT. We confirm that the values used in the analysis represent the ratio of
DOT of the API therapies. To correct for differences in posology among compounds, the
daily defined dose (DDD, the assumed average maintenance dose per day for a drug used
for its main indication in adults) was calculated on the basis of DDD data published by the
WHO, and DDD correction was applied to sales data [51,52]. Sales data available for each
brand were aggregated at the active ingredient level for each ATC group, and quarterly
data were summarized annually.
To estimate prices, manufacturer revenues and volume (CU) data were used, and prices
were estimated for DDD-adjusted quantities separately. This estimate does not provide
consumer prices, but the aim was to analyse aggregate data at the active ingredient level and
to examine the long-term relative market performance of each active ingredient in different
countries. As the demand of the pharmaceutical market is the outcome of decisions taken
by several players on the consumer side, it seemed to be more appropriate to estimate the
manufacturer prices of active ingredients. Data were processed with Microsoft Excel 2010
and Stata IC 13.1 software (StataCorp LLC Lakeway Drive, College Station, TX, USA).
2.2. Multidimensional Scaling and Indicators for Interpretation
Subsequent to the necessary data conversion, multidimensional scaling was under-
taken to analyse drug sales of the C09 ATC group, applying the methodology suggested
by Kovács and Simon for both single-drug formulations and combination drugs. Multidi-
mensional scaling is a method that facilitates the comparison of objects based on the level
of similarity while taking multiple variables into consideration. The method is capable
of exploring the structure of data in such a way that objects are represented as geometric
relationships among points in a multidimensional space. The advantage of the method
is the resulting graphic display that illustrates the magnitude of differences between the
objects, showing which ones are close to each other. The statistical reliability and validity
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of the solution is measured by the value of R2 and a stress indicator. The method does
not provide a direct solution for interpreting the dimensions of the space of perception
and object characteristics. We interpreted the results based on professional experience
and by collating the multidimensional scaling output with the indices derived from sales
data. In our analysis, countries were located as objects in the multidimensional space, and
similarity data were derived from their characteristics [53,54]. Aiming to compare the data
of nine countries, the analysis was performed by the “classical” method available in Stata
on annual DDD-adjusted data for the different years.
In data analysis, clinical and pharmacy sales data, separately recorded in the database,
were summarized at the product group- and at the active ingredient-level; that is, both
clinical and retail sales data were considered. We calculated ARB and ACEI market char-
acteristics from raw data, and we worked out the input index numbers for this group
as follows:
1. ARB: ACEI price level ratio: ratio of ARB price level and ACE inhibitor price level,
calculated as the quotient of manufacturer sales revenue and sales volume;
2. ARB: ACEI volume ratio: ratio of ARB sales volume and ACE inhibitor volume;
3. ARB: ACEI sales revenue ratio: manufacturer sales revenue of ARBs and ACE inhibitors;
4. ARB preference index: ‘ARB: ACEI volume ratio’ (2) multiplied by ‘ARB: ACEI sales
revenue ratio’ (3). We used this variable as a composite index to estimate the bias
towards ARB use in relation to ACEIs despite the higher price levels.
The analysis was undertaken based on data for both single-drug formulations and
fixed-dose combination drugs. This article presents the results based on data that represent
all market, mono, and combination therapies taken together.
2.3. Approach to Analysing Changes in ACE Inhibitor and Arbs Sales Data over Time
To examine changes in market characteristics (namely, the relative sales data of indi-
vidual countries over time), we created the indices described above for data associated
with the years 2001, 2009, and 2016 at the beginning, middle, and end of the data series,
respectively. Single-drug formulations and combination drugs were also taken into account.
To visualize the changes, multidimensional scaling was undertaken.
Taking an explorative approach, we further investigated the market processes of the
active ingredients of ACE inhibitors, focusing on three of the above-mentioned Central and
Eastern European countries (Hungary, Poland, and Romania), in addition to three Western
European countries (France, Germany, and the UK).
To illustrate market competition, prices and the number of brands of the same active in-
gredient concurrently present in the market were plotted, as changes in prices and changes in
the number of available substitutes may indicate the start of generic competition. To charac-
terize the market concentration of ACE inhibitors, we calculated the Herfindahl–Hirschman
concentration index (both DDD and non-DDD adjusted HHI) for the selected years and
plotted it versus time. The analysis of relative market shares of ACE inhibitors together with
HHI calculations on non-DDD-adjusted data provided an overview of the relative sales of
individual dosage units (tablets, capsules, etc.) regardless of the doses applied.
3. Results: Development of Preferences for ARBs and ACE Inhibitors in Nine
European Countries
3.1. Market Features of ARBs and ACE Inhibitors in 2016, 2009 and 2001
In order assess the market performance trends of the two groups of antihypertensive
therapies, a short summary of their history should be given. Of the two mechanisms
of action, ACE inhibitors were the first therapies to be approved and launched from the
beginning of the 1980s (captopril, enalapril in 1980–1981, lisinopril, perindopril and ramipril
in 1987–1988–1989, respectively; other molecules followed afterwards). ACE inhibitors
lost their patent exclusivity mainly in the 1990s and early 2000s, and manufacturers tried
to prolong patent protection even through violations of the law (see the perindopril case
referenced above). The first ARB’s market entry occurred in 1995 with losartan (valsartan in
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1996, candesartan in 1997). Losartan and candesartan were made into generics at the very
beginning of the 2010s. Until 2016, all significant ARBs were genericized. The innovative
and generic market entries define market patterns in a very complex manner.
To describe the macro-level trends in the market performance, we used the methodol-
ogy described above. Analyses of aggregate sales revenues of ARBs and ACE inhibitors
were repeated on available data for 2001, the earliest year of the database, data for 2009,
from the middle of the period, and 2016 as the end of a 15-year trend. The indices were
created for comparison and multidimensional scaling was also carried out.
Considering the data for 2001 (Table 1), every market was dominated by ACE in-
hibitors. Two groups can be defined: the first group includes Hungary, Poland, and Ro-
mania, with practically no ARB sales; the second group involves Western countries, with
ARB sales volumes ranging between 14 and 37%. In the first group of countries, ARBs were
much more expensive than ACEIs (four to eight times more), while in the Western group,
ARBs were also more expensive on average, but to a lesser extent, if we compare the relative
prices. All ARB preference indices were below “1” in 2001 as opposed to in 2009, despite
the fact that ARBs accounted for over 40% of the sales revenue in France and Spain.
Table 1. Market features of ARBs and ACE inhibitors in 2001 based on DDD-adjusted volumes, taking into consideration































FR 0.59 0.43 37.34 44.85 62.66 55.15 1.36 0.60 0.81 0.48
GE 0.57 0.27 21.61 36.81 78.39 63.19 2.11 0.28 0.58 0.16
HU 0.52 0.12 1.03 4.31 98.97 95.69 4.32 0.01 0.05 0.00
IT 0.53 0.38 24.75 31.56 75.25 68.44 1.40 0.33 0.46 0.15
PO 0.56 0.09 0.19 1.16 99.81 98.84 6.01 0.00 0.01 0.00
RO 0.82 0.10 0.09 0.69 99.91 99.31 8.16 0.00 0.01 0.00
SP 0.46 0.24 29.99 45.47 70.01 54.53 1.95 0.43 0.83 0.36
UK 0.81 0.36 14.23 27.11 85.77 72.89 2.24 0.17 0.37 0.06
Abbreviations: FR—France, GE—Germany, HU—Hungary, IT—Italy, PO—Poland, RO—Romania, SP—Spain, UK—United Kingdom.
Assessing the data from 2009 shows that ARB relative prices were conspicuously
higher in the investigated group of countries (Table 2). For instance, the difference in cost
between the two drug groups varied by a factor of ten in Germany and in the UK. Presum-
ably as a consequence, the volume share of ARBs exceeded that of the ACE inhibitors only
in two countries (France and Spain). The market share of ACE inhibitors accounted for
70–90% of the DDD-adjusted sales volume in Germany, Hungary, Poland, Romania, and
the UK, and in the three Central Eastern European countries this drug group accounted for
the majority of manufacturing revenues, too. With the exception of the UK, the preference
index exceeded “1” in every Western European country, with Spain, the Netherlands, and
France having the highest value. ARBs were more expensive in 2009 than in 2016, and in
most Western European countries with similar volume shares, shares of manufacturing
revenue were also higher.
Table 2. Market features of ARBs and ACE inhibitors in 2009 based on DDD-adjusted volumes, taking into consideration































FR 0.54 0.29 54.79 68.92 45.21 31.08 1.83 1.21 2.22 2.69
GE 0.54 0.05 26.35 79.20 73.65 20.80 10.64 0.36 3.81 1.36
HU 0.36 0.10 14.32 37.93 85.68 62.07 3.66 0.17 0.61 0.10
IT 0.45 0.16 41.44 65.94 58.56 34.06 2.74 0.71 1.94 1.37
NE 0.51 0.07 43.55 85.52 56.45 14.48 7.66 0.77 5.91 4.56
PO 0.17 0.06 11.30 26.86 88.70 73.14 2.88 0.13 0.37 0.05
RO 0.28 0.08 13.35 34.06 86.65 65.94 3.35 0.15 0.52 0.08
SP 0.48 0.10 55.30 85.05 44.70 14.95 4.60 1.24 5.69 7.04
UK 0.37 0.04 22.32 74.76 77.68 25.24 10.31 0.29 2.96 0.85
Abbreviations: FR—France, GE—Germany, HU—Hungary, IT—Italy, NE—The Netherlands, PO—Poland, RO—Romania, SP—Spain,
UK—United Kingdom.
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In general terms—based on DDD-adjusted sales figures in 2016—the volume share of
ACE inhibitors was greater than that of ARBs, so the trend for increasing ARB sales that we
observed between 2001 and 2009 did not continue (Table 3). France, Spain, the Netherlands
and Italy accounted for the greatest ARB share of DDD-adjusted volume, exceeding 50%
in the first two countries, while the market share in Italy and the Netherlands was more
than 40%. In contrast, ACE inhibitors accounted for more than 70% of the DDD-adjusted
sales volume in Poland, UK, and Romania. In Poland and Romania, ACE inhibitors also
accounted for the majority of manufacturing revenue, similarly to in Hungary, the third
Central and Eastern European country. In other countries, ARBs accounted for the larger
share of manufacturing revenue. In Spain and Germany, ARBs accounted for over three-
quarters of the sales revenue of the whole drug group. The difference in average price
level of ACE inhibitors and ARBs—a possible cause and effect of these effects—was also
highest in these two countries, as was the ARB preference index. The ARB preference
index, reflecting the relative sales and estimated price levels of the two subgroups together,
was 1.95 and 5.83 in the German and Spanish market, respectively, indicating significant
ARB sales despite their high price in relation to that of ACEIs. A value of around “1” for
France, Italy, and the Netherlands indicates balanced market conditions, while a value in the
range of 0.1–0.3 for Poland, Hungary, and the UK indicates the market dominance of ACE
inhibitors. ACE inhibitors were generally cheaper than ARBs in all nine of the countries,
although the price ratio shows that the gap clearly closed between 2009 and 2016.
































FR 0.20 0.15 50.63 57.04 49.37 42.96 1.29 1.03 1.33 1.36
GE 0.19 0.04 37.56 76.44 62.44 23.56 5.39 0.60 3.24 1.95
HU 0.10 0.09 27.07 29.48 72.93 70.52 1.13 0.37 0.42 0.16
IT 0.22 0.12 43.85 58.65 56.15 41.35 1.82 0.78 1.42 1.11
NE 0.07 0.04 45.42 59.88 54.58 40.12 1.79 0.83 1.49 1.24
PO 0.11 0.05 25.04 40.69 74.96 59.31 2.05 0.33 0.69 0.23
RO 0.12 0.07 28.44 40.61 71.56 59.39 1.72 0.40 0.68 0.27
SP 0.31 0.06 51.66 84.52 48.34 15.48 5.11 1.07 5.46 5.83
UK 0.10 0.03 22.71 52.12 77.29 47.88 3.70 0.29 1.09 0.32
Abbreviations: FR—France, GE—Germany, HU—Hungary, IT—Italy, NE—The Netherlands, PO—Poland, RO—Romania, SP—Spain,
UK—United Kingdom.
Comparison of the results of multidimensional scaling for 2016, 2009, and 2001 (Figure 1)
shows the clear dominance of ACEI therapies in 2001 (countries are close to “0” in relation
to dimension 2), with ARBs having been available for only a few years. Until 2009, a trend
for the increasing use of ARBs can be seen, which may be explained by their acceptance,
and, by 2009, the maturity of innovative ARB brands. The increase in ARB sales happened
in spite of the significant price index increase between ACEIs and ARBs (with ARBs being
1.83–10.64 times more expensive than ACEIs in different countries). The reason for this is the
genericization of ACEI brands, which pushed prices down, while ARB active ingredients
maintained their innovative status and monopoly. Accordingly, competition in the ACEI
markets occurred at the level of brands, and in ARB markets at the level of APIs. Until 2016,
both ARB and ACE prices dropped significantly, and the scissor of the price index between
the two groups also closed to a range of 1.13–5.11, still in favour of ARBs. Interestingly,
although the price level of ARBs decreased and their relative price compared to ACEIs also
decreased in the examined period, the dominance of ARB sales volumes did not follow this
trend, ending up with almost the same volume ratio between ACEIs and ARBs in 2016 as in
2009. For this reason, the multidimensional scaling indicates a closing pattern.
Considering the countries in the study, it is clear that although the relative position of
Western European countries changed, the situation of the three Eastern European countries—
in which the lower level of use of ARBs is reflected—remained relatively similar and
differentiated from the Western countries. However, in 2009, before the launch of generic
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ARBs, the German and the British markets formed one group identifiable by less frequent
use of ARBs. Additionally, the Italian and French as well as the Dutch and Spanish country
pairs can also be distinguished in 2009. These pairs, comparing the figures from the tables
above, had very similar relative prices for ARBs and the ACEI group, and the pairs also had
a very similar share of the ARB market. The stress index fits the data for all years well.
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The trends can be better assessed, and countries can be more sharply differentiated if
the ARB preference index and price levels are plotted over time, year by year (Figure 2).
In the UK, Hungary, Poland, and Romania, the preference index remained invariably low
in the period under analysis. In contrast, despite the high prices, ARBs were responsible
for a significant share of the m rke in the other five countries, leading to a pe k in the
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Figure 2. ARB preference index and average ARB and ACEI prices.
Along with the drastic price decline in generic drugs, the market share of ARBs
increased in the three Central Eastern European countries and Germany; however, in France,
Spain, Italy, and the Netherlands, in around 2010, when prices started to drop, the volume
share of ARBs stopped growing. It should be emphasized that the average price level of
ARBs in all countries was higher than that of ACE inhibitors during the whole period, but
the relative price difference between ARBs and ACE inhibitors tended to decrease in all
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countries. In Hungary and the Netherlands, the price of ARBs has been close to that of
ACE inhibitors in recent years, and in Romania and Poland, price levels have also become
significantly closer. The biggest gap between price levels remains in the Spanish market.
3.2. Preferences for ACE Inhibitor Active Ingredients in Six European Countries
After the comparison of the two therapeutic groups, the evaluation now changes the
focus to ACEI therapies. Kovács and Simon assumed a positive correlation between clinical
evidence and market performance, presumably leading to ramipril sales outperforming
other drugs in terms of volume. To better understand the trends in market share changes
and the reasons behind them, we analyse the market factors of ACEI therapies in the
period under review. In addition to the three Central Eastern European countries, we
compare performance trends in Germany, France, and the UK. In the examination of active
ingredients, we help to interpret the diffusion patterns by assessing the number of brands,
volume shares, and price levels.
The sales volume of ACE inhibitors generally increased in the selected European
countries in the examined period. The market shares for DDD-adjusted volumes (Figure 3)
reveal that the diffusion of dominant drugs formed the market landscape in the investigated
period. By 2016, with the exception of Hungary and Romania (where perindopril was the
most popular drug), ramipril became the market-leading therapy. In the UK, ramipril has
been responsible for the largest market share since the mid-2000s. However, in Germany
and Poland, following 2007–2008, it replaced the former market-leading drug enalapril
within a few years. In France, the sales volume of perindopril approached that of ramipril,
and since about 2008, the market share of the two active ingredients has stabilized. Similarly,
the market share of perindopril has also been increasing in Hungary and Romania since
2008. The market share of enalapril was very significant in Poland, Hungary, Germany, and
Romania in the early 2000s, but afterwards decreased significantly in almost all countries.
Captopril, the first ACEI, also had a large market share in the Romanian and German
market at the dawn of the 2000s, but declined in significance by the end of the period.
Lisinopril had a larger market share primarily in France, Germany, and the UK, but with
the exception of the UK, its relative market share decreased. It is surprising that, in contrast
to in other countries, the relative sales of various active ingredients have not changed much
in France and Poland since 2011–2012, apart from the slow decrease in sales of lisinopril
and enalapril in favour of perindopril and ramipril. Interestingly, the growth rate of the
market share of ramipril slowed down temporarily for a period of three or four years after
2004, when the share of perindopril increased.
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Apart from the above-discussed products, other active ingredients assumed minor
significance only, yet some country-specific features are worth mentioning. Trandolapril
had a noticeable market share in the French and Romanian market in the early 2000s, and
zofenopril only in Romania, with a very small market share in France and Poland. Cilazapril
had a noticeable market share mainly in the Polish market, quinapril in the Polish, Romanian,
and French markets, and fosinopril in the Hungarian, Romanian, and French markets.
The market performance of active ingredients is defined by multiple factors as we
described it in in the literature review. To establish a clear picture, price levels, number
of brands, and DDD-adjusted volume shares of the five most significant drug therapies
in terms of market share—captopril, enalapril, lisinopril, perindopril, and ramipril—are
plotted in Figure 4. This graph shows that the prices of the most frequently used ACE
inhibitors decreased between 2001 and 2016. The inversely proportional impact of the
increase in the number of brands on price levels can also be confirmed, with ramipril
falling significantly in every market, but perindopril falling less significantly relative to
ramipril, with almost no change in Germany. The price of enalapril has not changed in
France, nor zofenopril in France and Romania, nor lisinopril in Hungary. Considering
prices in general, those for active ingredients with lower sales volumes tended to be higher.
Ultimately, the price of ramipril was among the lowest in every market during the last few
years of the period under analysis.
The total number of ACE inhibitor brands continued to increase until around 2010,
before declining or stagnating in most countries. In Germany, the number of brands topped
out somewhat earlier, in around 2007, but then decreased faster than in other countries due
to the sharp decline in the number of captopril brands. The number of perindopril brands
soared between 2008 and 2010 (except for in Germany), after which active ingredients with
larger market shares (captopril, lisinopril, perindopril, ramipril, enalapril, trandolapril,
quinapril, and fosinopril) all became members of a multi-player market. This coincided
with the period when the number of ARB active ingredient brands started to increase.
In contrast, the price of single-drug ACE inhibitors—with the exception of perindopril—
started to decline in most countries in around 2005, with an increase in the number of
brands concurrently, followed by combination drugs a few years later.
In most countries, the price and the market share of captopril, enalapril, and lisinopril
continuously declined over the period, while the number of brands of enalapril and captopril
started to grow in the early 2000s, then more or less stabilized and then started to decline.
Unlike in other countries, the price of captopril in Hungary slowly increased until 2010, and
in the UK, prices shot up between 2013 and 2015 (the paradox of generics). One feature
of lisinopril should be emphasized: the Polish and the Romanian markets show a slight
increase in the market share after the fall in prices in around 2005. In France, the fall in
prices and sharp increase in the number of brands of perindopril and ramipril indicates the
market entry of generic drugs in around 2005 and 2008. Before that, the market share of the
two active ingredients increased, but remained essentially unchanged for the remainder of
the period. In the German, Polish, and British markets, the volume share of perindopril
did not change significantly, despite the fall in prices, but the market share of ramipril
increased rapidly following the decrease in prices and the growth in brand numbers in the
three markets mentioned above, and in Hungary and Romania as well. Interestingly, in the
UK, the growth rate fell slower than previously. However, the market share of perindopril
grew steadily in the Hungarian and Romanian markets. Here, despite the rapid rise in the
number of brands, prices declined at a slower rate.
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Market fragmentation or concentration is best measured by the Herfindahl–Hirschman
index (HHI). Annual HHI scores for the markets of ACE inhibitor active ingredients in six
countries are presented in Figure 5. The fig re shows the outcomes of the DDD-adjusted
volume- and revenue-based calculations; furthermore, eference raw calculations—that is,
c r ectio -free daily dos calcul tions—are also presented. With he strengthening market
position of ramipril in Western countries, and that of perindopril in Fra ce, it is not sur-
prising that the HHI scores continuously grew in these countries. Concurrently, relatively
concentrated markets started to become increasingly fragmented and HHI declined in CEE
countries by the end of the 2000s, before starting to rise again with the growing dominance
of ramipril and perindopril. Interestingly, the HHI scores of raw and DDD-adjusted volume
figures started to diverge increasingly in Germany, the UK, and Poland, where ramipril had
the largest market share. The reason for this may be that ramipril, in contrast to perindopril,
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is used in much higher doses than DDD in clinical practice. As with the market share
figures, market concentration was no longer on the rise in Poland after 2011–2012.
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4. Discussion, Conclusions, Practical Implications
The diffusion of in ovative and generic drugs and changes in prescription preferences
involves a complex process in which market positions are defined by the pharmaceutical
market players and the characteristics of competing drugs. One of the characteristics of
the pharmaceutical market is that only similarly or equally effective innovative products
can compete with each other until the expiry of their patents or market exclusivity. This
phenomenon can be clearly seen if we consider the decline in the use of captopril, the first
line of therapy of the two groups, but an insignificant player by the end of the examined
period. Captopril was outperformed by better candidates over the decades.
In the generic market for active ingredients, decades-old innovations are present and
access to them is improving due to falling prices and an i creasing numb r of market
players. This also mea s that there is much more knowledg about a few active ingredients
(and whole groups of them) than about ent rely new, pioneering th rapies—so, acc rding to
Kovács and Simon, generic markets may play a major role in the s read of better therapies
from a clinical point of view. Considering aggregate, long-term change in sales volumes,
two conclusions can be drawn. A comparison of ARB and ACEI therapies shows that the
increasing dominance of ARBs in European markets cannot be identified, which, in spite of
the decreasing price and clinical superiority of ARBs, may be a negative outcome from the
patient’s perspective. On the contrary, in terms of ACEI sales volumes, ramipril has been
the most popular option, which is a positive outcome from the same perspective based on
a ranking of evidence-based principles.
One of the most striking features of the time-series data is th t in Hungary, Romania,
and Poland, the sales revenues f the ARB drug group increased in line with the emerg nce
of generic drugs—ev n if slowly and from a low b seline. However, a d xcept for Germany,
this is not the case for the Western European countries. In the case of th latter, with th
diffusion of generic drugs, ARB sales stagnated in the 2010s, and the market share in relation
to ACE inhibitors remained virtually unchanged, despite the decline in ARB prices. It seems
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that the initial spread of ARBs was not hindered by high prices in most Western countries,
but the availability of generic drugs improved access to ARBs in the German and three
Eastern European markets. An explanation for the flattening volume curves of ARBs and
ACE inhibitors in Western countries is that Western markets that started to use ARBs earlier
became saturated, meaning that the number of untreated patients requiring angiotensin
medication had become very small by the end of the period. This may be true for the
Netherlands, the UK, and Italy, where the sales data of both ACE inhibitors and ARBs, after
reaching a plateau, remained largely unchanged for a longer period. In contrast, although
ARB sales stagnated in Spain and France after 2010, sales of ACE inhibitors increased almost
linearly. An important factor behind this trend is hypothesized to be the difference between
the level of competition between the two drug groups. Until the 2010s, ARBs, associated
with a monopoly and high prices, competed on the level of the API. In contrast, ACE
therapies started to compete on the brand level with multiple generic entries, pushing prices
down and boosting diffusion in relation to ARB therapies. Accordingly, the diffusion of
the therapeutic groups seems to have been strongly affected by the difference between the
level of competition. Price sensitivity, drug policies, and regulations are thought to be key
additional factors that define diffusion at the country level.
In the 2000s, increasing expenditure both in France and Spain led to regulations aimed at
reducing spending on pharmaceuticals [55,56]. Looking at ARB volume shares in 2016 again,
it can be seen that they were the highest in France and Spain: 50.63 and 51.66%, respectively
(slightly lower than in 2009). In contrast, the UK had the lowest share in 2016: 22.71%. In the
UK market, according to the NICE recommendation [57,58], ARB should only have been
prescribed in the case of intolerance or contraindication to ACE inhibitors before 2011, but
the 2011 directive [59] also recommended the use of cheap ARBs as a first-line approach.
Nevertheless, the market share of ARBs in the UK remained essentially unchanged after 2005.
The almost unchanged mid-term market share suggests that prescribing habits are fixed, at
least at the therapeutic group level. One limitation of this study is that the role of promotional
activities cannot be explained from the data, and thus should be further investigated.
Turning the focus to the investigation of ACEI therapies, the most significant active
ingredients became generic ones in the nine countries in the 2000s. Competition existed
mainly among generic drugs, even if active ingredients with low sales had no or very few
competitors on European markets. Thus, data for the first half of 2016 reflect well-developed
generic market conditions, if not necessarily perfect competition. Based on our results, we
draw the conclusion that ramipril outperformed its competitors in the long term. By 2016,
with the exception of Hungary and Romania, where perindopril was the most popular drug,
ramipril continuously became the market-leading therapy. The European markets that
were investigated by the end of the period can be symbolized by the competition between
ramipril and perindopril, with two other compounds also competing for sales (lisinopril and
enalapril), and others declining in significance. The diffusion of clinically preferred therapies
was strongly supported by the generic entries, and the inversely proportional impact of
the increase in the number of brands on the price level can also be confirmed: the price
of ramipril fell significantly in every market, but that of perindopril fell less significantly
relative to ramipril, with almost no change in Germany.
Interpreting the results with Denig’s model, in countries such as France, Spain, Italy,
and the Netherlands, it is more likely that drugs enter the typical medical ‘evoked set’ start
before genericization, while in other countries such as Poland, Romania, and Hungary, this
process occurs after genericization. Alternatively, and as an analogy of Rogers’ model of
innovation diffusion, Eastern European countries may be perceived as late adopters of new
ACE inhibitors and ARBs. However, it is doubtful as to whether the existence of late users
is really related to uncertainty about new technology, as suggested by Rogers, not to the
pricing of medicines. The phenomenon that manufacturers tend to enter markets with higher
potential should also be considered—this defines the order of penetration, starting from
Western countries towards Eastern ones. The significance of this phenomenon is nowadays
outweighed by regulatory issues, since new chemical entities must be authorized through
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a centralized procedure, but this was not the case when the compounds we investigated
were registered.
The impact of marketing activities can only be assumed with limitations due to the
aggregate data. Country-origin effects suggested by Kovács and Simon cannot be excluded
for perindopril or lisinopril, even if long-term sales revenues are examined. The market
share of perindopril in the French, Romanian, and Hungarian markets was significant for
most of the period examined. On the other hand, the rate of market share change was
slightly different: in France, the share remained unchanged from 2009 onwards, while in the
Hungarian market, the share of perindopril accelerated from around the same time, while
in Romania growth has been almost linear since the early 2000s. The number of perindopril
brands on the market increased dramatically between 2008 and 2010, suggesting that the
emergence of generic competition was more conductive to the diffusion of active ingredients
in Hungary, but in France, similarly to ramipril, growth was interrupted following the
emergence of perindopril generic drugs. In Romania, the entry of generic drugs had little
effect on the market dynamics of perindopril diffusion. At the same time, in the Hungarian,
Polish, and Romanian markets, the market share of ramipril, similarly to that of ARBs,
increased along with price reductions and the emergence of generic competition. This
suggests that in the three Eastern European countries, the proliferation of new therapies
was less influenced by manufacturers’ promotions than by price competition as a result
of the entry of generic drugs, allowing for the wider use of more advanced treatments.
Interestingly, even in the cost-conscious UK market that was dominated strongly by ramipril,
revenue-based data suggest that, until genericization, the promotion of perindopril slowed
down the diffusion of the generic and cheap ramipril. When assessing the competition, we
should not forget the lawsuit related to perindopril. The violation of competition, alongside
the other important factors described above, may have had an important impact on market
performance that we can observe at the end of the period.
In Eastern European countries, the emergence of generic markets has not only improved
access to ACE inhibitors and ARBs, but has been a prerequisite for changing preferences. In
contrast, genericization resulted in the relative anchoring of preferences in some Western
European countries, which phenomenon may be attributed to the role of the cessation
of promotion.
The temporal change in the Herfindahl–Hirschman index is somewhat similar in the
three CEE countries, especially when compared to that for the Western countries. From
the early 2000s onwards, the HHI for both manufacturing revenues and sales revenues
indicates a declining concentration, which reverses after 2006–2007. In contrast, French,
German, and British data show a near-constant increase in market concentration. With
regard to the market share of active ingredients, this is primarily due to the steady decline
in the large share of enalapril (and captopril in Romania) in the early 2000s. Thus, the
market share of newer therapies (ramipril, lisinopril, and perindopril) was greater in the
three Western countries compared to in Eastern European countries, where initially the
older and cheaper active ingredients were more prevalent.
A limitation of the study is that, although goods can move freely within the EU,
healthcare financing is essentially within the jurisdiction of member states; furthermore,
Hungary, Poland, and Romania joined the EU during the period under examination (the
effect of parallel imports was also not taken into account). In addition, many other political
and economic changes have taken place in the countries during this period, and health
reforms and the economic crisis of 2007–2008 limit the interpretability of the data presented
here. Additionally, survey data do not cover the entire European Union, which also imposes
limits on the generalizability of conclusions. Finally, it should be mentioned again that
long-term aggregate sales data were analysed, without taking pharmaceutical promotion or
differences in approved indications into deeper consideration, and so only assumptions can
be made about the latter relationships. We admit that the correlation between the clinical
evidence and the market performance is strongly biased by multiple factors where the
prescribing physician plays the key role. The assessment of the different factors that affect
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the perception of the physician is the key to understanding the trends that we describe in
the current study. Based on the results, the authors suggest further in-depth investigation
of the multi-factorial relationships that finally leads to drug prescriptions.
In terms of practical impacts, it is recommended that innovative pharmaceutical com-
panies, when designing their promotional activities, assess and consider market character-
istics and limit their spending in markets where the entry of generics is more permissive.
However, in markets where several ‘me-too’ players are concurrently present, generic
manufacturers should pay attention to the promotion of innovators, in addition to the
sales trends of the last few years prior to the termination of market exclusivity, since when
the promotion of the entry of generic drugs is cut back, revenues from sales of active
ingredients may not increase as expected. Additionally, it may be worthwhile to conduct
research into evoked sets among potential prescribers to map out their prescription pat-
terns. Considering the case of ramipril, generic manufacturers should seek to identify drug
therapies with better safety and efficacy profiles that, in the long term, can contribute to
more sales and higher profits.
Furthermore, it may be beneficial for funding institutions, along with medical and
pharmaceutical professional organizations, to formulate national recommendations even
within drug classes at an active substance level to reduce expenditure on and promote the
uptake of more advanced medicines in generic markets.
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